|
Clinical Insight for Cancer Care in China
Access to healthcare in China has improved significantly over the last two decades as the country has undergone dramatic economic development. Understanding the demographics, lifestyle shift, increased access to healthcare, and current standards of care is imperative for supporting strategic commercialization decisions in China’s dynamic and emerging oncology care market.
CancerMPact® Treatment Architecture China 2009 is a clinical rich multiclient report that focuses on the largest tumor types in China. The reports cover an in-depth analysis of treatment and drug utilization and provide an assessment of current clinical management of cancer by stage for all treatment modalities, including chemotherapy. The tumor-type reports are freestanding and include:
- Colorectal cancer
- Esophageal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Non-small cell lung cancer
Supports Actionable Decision-Making in the Chinese Pharma Market
CancerMPact® Treatment Architecture China 2009 gives pharmaceutical companies the clinical depth and insight to support actionable decisions and provide the basis to:
- Plan product positioning and take advantage of a dynamic market on the verge of introducing universal healthcare coverage
- Produce more accurate market assessments, leading to targeted sales approaches
- Set a strategy to capitalize on opportunities, such as where to introduce new therapeutic regimens
- Gain perspective on targeted audiences regarding whom they treat and how they treat them
- Compare treatment modalities across China, the U.S., and Japan
Download a Fact Sheet
For more information on MattsonJack's oncology
services or knowledgeware products, phone: 650.403.7001 or e-mail us at info@mattsonjack.com.
|
